Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody

Ryo Hatano, Kei Ohnuma, Junpei Yamamoto, Nam H. Dang, Taketo Yamada, Chikao Morimoto

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

CD26 (DPP4) is a T cell costimulatory molecule as well as T cell activation marker, and CD26+ T cells are accumulated in inflamed tissues, such as rheumatoid synovitis and autoimmune thyroiditis. In the present study, we found accumulation of CD26+ T cells in graft-versus-host disease (GVHD) target organs. To expand our in vitro findings to an in vivo system, we examined CD26-dependent organ injury in a xenogeneic GVHD (x-GVHD) murine model. Following intraperitoneal injection of human peripheral blood mononuclear cells into non-obese diabetic severe combined immunodeficiency/γc -/- mice (hu-PBL-NOG mice), the mice exhibited the onset of GVHD symptoms associated with the presence of CD26high human lymphocytes in the peripheral blood and GVHD target tissues. Administration of humanized anti-human CD26 monoclonal antibody (mAb) decreased x-GVHD severity and prolonged survival in hu-PBL-NOG mice without loss of engraftment of human T cells, while increasing doses of CTLA4- immunoglobulin fusion protein diminished engraftment of human lymphocytes. Importantly, anti-CD26 mAb treatment preserved the graft-versus-leukaemia effects in studies using cotransplantation of P815 murine leukaemic cells. In addition, CD26+ lymphocytes infiltrated the GVHD patients' target tissues. Altogether, our data indicate a role for CD26 in the regulation of GVHD and point to CD26 as a novel target for therapeutic intervention in this disease.

Original languageEnglish
Pages (from-to)263-277
Number of pages15
JournalBritish Journal of Haematology
Volume162
Issue number2
DOIs
Publication statusPublished - 2013 Jul

Fingerprint

Graft vs Host Disease
Monoclonal Antibodies
T-Lymphocytes
Lymphocytes
Autoimmune Thyroiditis
Severe Combined Immunodeficiency
Synovitis
Intraperitoneal Injections
Immunoglobulins
Blood Cells
Leukemia
Transplants
Survival
Wounds and Injuries
Therapeutics
Proteins

Keywords

  • CD26 (DPP4)
  • Graft-versus-host disease
  • Haematopoietic stem cell transplantation
  • T cell costimulation

ASJC Scopus subject areas

  • Hematology

Cite this

Hatano, R., Ohnuma, K., Yamamoto, J., Dang, N. H., Yamada, T., & Morimoto, C. (2013). Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. British Journal of Haematology, 162(2), 263-277. https://doi.org/10.1111/bjh.12378

Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. / Hatano, Ryo; Ohnuma, Kei; Yamamoto, Junpei; Dang, Nam H.; Yamada, Taketo; Morimoto, Chikao.

In: British Journal of Haematology, Vol. 162, No. 2, 07.2013, p. 263-277.

Research output: Contribution to journalArticle

Hatano, R, Ohnuma, K, Yamamoto, J, Dang, NH, Yamada, T & Morimoto, C 2013, 'Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody', British Journal of Haematology, vol. 162, no. 2, pp. 263-277. https://doi.org/10.1111/bjh.12378
Hatano, Ryo ; Ohnuma, Kei ; Yamamoto, Junpei ; Dang, Nam H. ; Yamada, Taketo ; Morimoto, Chikao. / Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. In: British Journal of Haematology. 2013 ; Vol. 162, No. 2. pp. 263-277.
@article{d48998e6d70d434cab90d6ee6e1c569c,
title = "Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody",
abstract = "CD26 (DPP4) is a T cell costimulatory molecule as well as T cell activation marker, and CD26+ T cells are accumulated in inflamed tissues, such as rheumatoid synovitis and autoimmune thyroiditis. In the present study, we found accumulation of CD26+ T cells in graft-versus-host disease (GVHD) target organs. To expand our in vitro findings to an in vivo system, we examined CD26-dependent organ injury in a xenogeneic GVHD (x-GVHD) murine model. Following intraperitoneal injection of human peripheral blood mononuclear cells into non-obese diabetic severe combined immunodeficiency/γc -/- mice (hu-PBL-NOG mice), the mice exhibited the onset of GVHD symptoms associated with the presence of CD26high human lymphocytes in the peripheral blood and GVHD target tissues. Administration of humanized anti-human CD26 monoclonal antibody (mAb) decreased x-GVHD severity and prolonged survival in hu-PBL-NOG mice without loss of engraftment of human T cells, while increasing doses of CTLA4- immunoglobulin fusion protein diminished engraftment of human lymphocytes. Importantly, anti-CD26 mAb treatment preserved the graft-versus-leukaemia effects in studies using cotransplantation of P815 murine leukaemic cells. In addition, CD26+ lymphocytes infiltrated the GVHD patients' target tissues. Altogether, our data indicate a role for CD26 in the regulation of GVHD and point to CD26 as a novel target for therapeutic intervention in this disease.",
keywords = "CD26 (DPP4), Graft-versus-host disease, Haematopoietic stem cell transplantation, T cell costimulation",
author = "Ryo Hatano and Kei Ohnuma and Junpei Yamamoto and Dang, {Nam H.} and Taketo Yamada and Chikao Morimoto",
year = "2013",
month = "7",
doi = "10.1111/bjh.12378",
language = "English",
volume = "162",
pages = "263--277",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody

AU - Hatano, Ryo

AU - Ohnuma, Kei

AU - Yamamoto, Junpei

AU - Dang, Nam H.

AU - Yamada, Taketo

AU - Morimoto, Chikao

PY - 2013/7

Y1 - 2013/7

N2 - CD26 (DPP4) is a T cell costimulatory molecule as well as T cell activation marker, and CD26+ T cells are accumulated in inflamed tissues, such as rheumatoid synovitis and autoimmune thyroiditis. In the present study, we found accumulation of CD26+ T cells in graft-versus-host disease (GVHD) target organs. To expand our in vitro findings to an in vivo system, we examined CD26-dependent organ injury in a xenogeneic GVHD (x-GVHD) murine model. Following intraperitoneal injection of human peripheral blood mononuclear cells into non-obese diabetic severe combined immunodeficiency/γc -/- mice (hu-PBL-NOG mice), the mice exhibited the onset of GVHD symptoms associated with the presence of CD26high human lymphocytes in the peripheral blood and GVHD target tissues. Administration of humanized anti-human CD26 monoclonal antibody (mAb) decreased x-GVHD severity and prolonged survival in hu-PBL-NOG mice without loss of engraftment of human T cells, while increasing doses of CTLA4- immunoglobulin fusion protein diminished engraftment of human lymphocytes. Importantly, anti-CD26 mAb treatment preserved the graft-versus-leukaemia effects in studies using cotransplantation of P815 murine leukaemic cells. In addition, CD26+ lymphocytes infiltrated the GVHD patients' target tissues. Altogether, our data indicate a role for CD26 in the regulation of GVHD and point to CD26 as a novel target for therapeutic intervention in this disease.

AB - CD26 (DPP4) is a T cell costimulatory molecule as well as T cell activation marker, and CD26+ T cells are accumulated in inflamed tissues, such as rheumatoid synovitis and autoimmune thyroiditis. In the present study, we found accumulation of CD26+ T cells in graft-versus-host disease (GVHD) target organs. To expand our in vitro findings to an in vivo system, we examined CD26-dependent organ injury in a xenogeneic GVHD (x-GVHD) murine model. Following intraperitoneal injection of human peripheral blood mononuclear cells into non-obese diabetic severe combined immunodeficiency/γc -/- mice (hu-PBL-NOG mice), the mice exhibited the onset of GVHD symptoms associated with the presence of CD26high human lymphocytes in the peripheral blood and GVHD target tissues. Administration of humanized anti-human CD26 monoclonal antibody (mAb) decreased x-GVHD severity and prolonged survival in hu-PBL-NOG mice without loss of engraftment of human T cells, while increasing doses of CTLA4- immunoglobulin fusion protein diminished engraftment of human lymphocytes. Importantly, anti-CD26 mAb treatment preserved the graft-versus-leukaemia effects in studies using cotransplantation of P815 murine leukaemic cells. In addition, CD26+ lymphocytes infiltrated the GVHD patients' target tissues. Altogether, our data indicate a role for CD26 in the regulation of GVHD and point to CD26 as a novel target for therapeutic intervention in this disease.

KW - CD26 (DPP4)

KW - Graft-versus-host disease

KW - Haematopoietic stem cell transplantation

KW - T cell costimulation

UR - http://www.scopus.com/inward/record.url?scp=84879841516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879841516&partnerID=8YFLogxK

U2 - 10.1111/bjh.12378

DO - 10.1111/bjh.12378

M3 - Article

C2 - 23692598

AN - SCOPUS:84879841516

VL - 162

SP - 263

EP - 277

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -